A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model

BACKGROUND: Multiple barriers exist for appropriate use of the proprotein convertase subtilisin/kexin type 9 enzyme inhibitors (PCSK9i) in patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) with inadequately controlled hypercholesterolemia despite stan...

Descripción completa

Detalles Bibliográficos
Autores principales: McCormick, Dana, Bhatt, Deepak L, Bays, Harold E, Taub, Pam R, Caldwell, Kim A, Guerin, Chris K, Steinhoff, Jeff, Ahmad, Zahid, Singh, Rubina, Moreo, Kathleen, Carter, Jeffrey, Heggen, Cherilyn L, Sapir, Tamar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391214/
https://www.ncbi.nlm.nih.gov/pubmed/33251993
http://dx.doi.org/10.18553/jmcp.2020.26.12.1517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391214/
https://www.ncbi.nlm.nih.gov/pubmed/33251993
http://dx.doi.org/10.18553/jmcp.2020.26.12.1517

Ejemplares similares